Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.79 |
| ▸ | CTSL | P07711 | 2/20 | 0.78 |
| ▸ | CA1 | P00915 | 2/20 | 0.77 |
| ▸ | CA2 | P00918 | 2/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.75 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199646 | 1.00 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL3440660 | 1.00 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL30383289 | 1.00 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL30415470 | 1.00 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL30384263 | 1.00 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL8977129 | 0.91 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL8977131 | 0.91 | ABCG2 (0.88) | ABCG2MEN1KMT2ATNFRSF1ACTSL | |
| SCHEMBL25197210 | 0.90 | CTSL (0.76) | ABCG2MEN1KMT2ACTSLCA1 | |
| SCHEMBL25184983 | 0.90 | CTSL (0.76) | ABCG2MEN1KMT2ACTSLCA1 | |
| SCHEMBL597849 | 0.90 | CAPN1 (0.82) | CTSLCA1CA2CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995006628-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-03-09 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | disclosed |
| WO-2009026658-A1 | PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026658-A1 | PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | disclosed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| EP-0634927-B1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | LICA PHARMACEUTICALS AS (DK) | 2001-07-04 | — | — | EP | disclosed |
| US-5985935-A | PARASITICIDES OR BACTERICIDES | STATENS SERUMINSTITUT (DK) | 1999-11-16 | — | — | US | disclosed |
| US-5525457-A | Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
| EP-0634927-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993017671-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885MEN1 3367/4885KMT2A 2792/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885MEN1 2457/4885KMT2A 3188/4885 |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | LIPC, CYP46A1, HMGCR | ABCG2 257/4885MEN1 4770/4885KMT2A 3515/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885MEN1 2457/4885KMT2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.